Trial Outcomes & Findings for Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia (NCT NCT00928720)

NCT ID: NCT00928720

Last Updated: 2018-07-03

Results Overview

A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

57 participants

Primary outcome timeframe

week 8

Results posted on

2018-07-03

Participant Flow

Participant milestones

Participant milestones
Measure
CES Device
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
No intervention; usual medical care for fibromyalgia
Overall Study
STARTED
19
20
18
Overall Study
COMPLETED
17
14
15
Overall Study
NOT COMPLETED
2
6
3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will received usual medical care for fibromyalgia
Total
n=46 Participants
Total of all reporting groups
Age, Continuous
51.9 years
STANDARD_DEVIATION 10.6 • n=5 Participants
51.5 years
STANDARD_DEVIATION 10.9 • n=7 Participants
48.6 years
STANDARD_DEVIATION 9.8 • n=5 Participants
50.8 years
STANDARD_DEVIATION 10.4 • n=4 Participants
Sex: Female, Male
Female
16 Participants
n=5 Participants
13 Participants
n=7 Participants
14 Participants
n=5 Participants
43 Participants
n=4 Participants
Sex: Female, Male
Male
1 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
3 Participants
n=4 Participants
Region of Enrollment
United States
17 participants
n=5 Participants
14 participants
n=7 Participants
15 participants
n=5 Participants
46 participants
n=4 Participants
Pain Numeric Rating Scale
5.8 units on a scale
STANDARD_DEVIATION 1.9 • n=5 Participants
5.7 units on a scale
STANDARD_DEVIATION 1.6 • n=7 Participants
6.0 units on a scale
STANDARD_DEVIATION 2.1 • n=5 Participants
5.8 units on a scale
STANDARD_DEVIATION 1.8 • n=4 Participants
Fatigue
6.12 units on a scale
STANDARD_DEVIATION 1.89 • n=5 Participants
6.66 units on a scale
STANDARD_DEVIATION 2.0 • n=7 Participants
6.85 units on a scale
STANDARD_DEVIATION 1.74 • n=5 Participants
6.53 units on a scale
STANDARD_DEVIATION 1.89 • n=4 Participants
Fibromyalgia impact
61.36 units on a scale
STANDARD_DEVIATION 18.2 • n=5 Participants
65.98 units on a scale
STANDARD_DEVIATION 17.9 • n=7 Participants
66.31 units on a scale
STANDARD_DEVIATION 16.9 • n=5 Participants
64.51 units on a scale
STANDARD_DEVIATION 17.5 • n=4 Participants
Depression
23.9 units on a scale
STANDARD_DEVIATION 11.8 • n=5 Participants
29.5 units on a scale
STANDARD_DEVIATION 13.7 • n=7 Participants
24.1 units on a scale
STANDARD_DEVIATION 14.2 • n=5 Participants
26.0 units on a scale
STANDARD_DEVIATION 13.3 • n=4 Participants
General sleep disturbance
3.75 units on a scale
STANDARD_DEVIATION 0.94 • n=5 Participants
4.01 units on a scale
STANDARD_DEVIATION 0.80 • n=7 Participants
3.6 units on a scale
STANDARD_DEVIATION 0.86 • n=5 Participants
3.8 units on a scale
STANDARD_DEVIATION 0.87 • n=4 Participants
Daily stress impact
3.86 units on a scale
STANDARD_DEVIATION 1.2 • n=5 Participants
3.05 units on a scale
STANDARD_DEVIATION 1.1 • n=7 Participants
3.39 units on a scale
STANDARD_DEVIATION 1.3 • n=5 Participants
3.44 units on a scale
STANDARD_DEVIATION 1.3 • n=4 Participants

PRIMARY outcome

Timeframe: week 8

A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
Pain Intensity Using Numeric Rating Scale
5.12 units on a scale
Standard Deviation 1.69
6.36 units on a scale
Standard Deviation 2.11
6.62 units on a scale
Standard Deviation 1.94

SECONDARY outcome

Timeframe: Week 8

A Numeric Rating Scale ranging from 0-10 to capture present levels of fatigue using the fatigue subscale of Lee's Fatigue Scale

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
Fatigue Using Lee's Fatigue Scale
4.97 units on a scale
Standard Deviation 2.45
6.38 units on a scale
Standard Deviation 2.2
6.83 units on a scale
Standard Deviation 2.35

SECONDARY outcome

Timeframe: Week 8

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
General Sleep Disturbance Scale
2.79 units on a scale
Standard Deviation 1.07
3.86 units on a scale
Standard Deviation 1.17
3.53 units on a scale
Standard Deviation 1.14

SECONDARY outcome

Timeframe: Week 8

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
Depression Using the CES-D
16.5 units on a scale
Standard Deviation 10.1
28.63 units on a scale
Standard Deviation 14.9
23.42 units on a scale
Standard Deviation 13.2

SECONDARY outcome

Timeframe: Week 8

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
Perceived Stress Using Numeric Rating Scale
3.93 units on a scale
Standard Deviation 2.4
5.64 units on a scale
Standard Deviation 2.66
5.29 units on a scale
Standard Deviation 2.61

SECONDARY outcome

Timeframe: Week 8

Outcome measures

Outcome measures
Measure
CES Device
n=17 Participants
cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
Sham Device
n=14 Participants
Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device. sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
Usual Care Alone
n=15 Participants
No intervention; participants will receive usual medical care for fibromyalgia
Functional Status Using the Fibromyalgia Index Questionnaire
45.05 units on a scale
Standard Deviation 16.3
70.1 units on a scale
Standard Deviation 22.3
63.2 units on a scale
Standard Deviation 19.9

Adverse Events

CES Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sham Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Usual Care Alone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Ann Gill Taylor, Professor Nursing

University of Virginia School of Nursing

Phone: 434-924-0113

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place